linjc16/ctgov huggingface dataset:
The Role of Netrin -1 in Acute Coronary Syndrome

Study Overview
=================
Brief Summary
-----------------
In our study, Netrin -1; We found that patients with ACS increased at the time of admission, decreased TIMI 3 flow after angiography, and higher risk groups in high risk groups such as TIMI and GRACE were found to have higher Netrin-1 levels.

Official Title
-----------------
The Effect of Serum Netrin-1 Levels on Diagnosis and Prognosis in Patients Presenting to the Emergency Department With Acute Coronary Syndrome

Conditions
-----------------
Acute Coronary Syndrome

Intervention / Treatment
-----------------
* Other: netrin-1 value on admission to hospital


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients over the age of 18 diagnose ACS patients undergoing angiography Exclusion Criteria: CVE history Neurological disease Pregnancy and Lactation Liver failure Diagnosed malignity Use of anticonvulsant and nephrotoxic medication Chronic kidney disease Not having angiography Developing acute renal failure after angiography Patients who rejected to participate were excluded.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Interventional Model Description: PATIENT AND CONTROL GROUP will be divided into two.
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: ACS GRUP<br>Demographic characteristics, history, vital signs, laboratory findings, coronary angiography (CAG) and echocardiography (ECO) findings of the patients were recorded. Netrin-1 levels were studied with blood collected at the hospital and 6-8 hours after CAG. CAG results were evaluated by TIMI flow. The patients were divided into two groups with and without TIMI 3 flow and Netrin-1 levels were compared. GRACE (Global Registry of Acute Coronary Events) and TIMI (Thrombolysis in Myocardial Ischemia) clinical risk assessments were performed and Netrin-1 values were compared. | Other: netrin-1 value on admission to hospital<br> <br> |
| Active Comparator: plasebo grup<br>It consisted of those without any disease and netri-1 values at admission were compared with the uptake patient group. | Other: netrin-1 value on admission to hospital<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| serum netrin-1 value | Netrin-1 in plasma was measured by enzyme-linked immunosorbent assay (ELISA) (Mybıosource MBS044526 ) All assays were performed in duplicate. Plasma Netrin-1 is expressed in picograms (pg) per mg. | 30 minute | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
netrin-1, acs, reperfuzion
Gastric Bacterial Colonization of Preterm Neonates

Study Overview
=================
Brief Summary
-----------------
This prospective cohort study was conducted in the Christiana Care Health System Neonatal Intensive Care Unit. It occurred at two time periods: Time period 1 included infants admitted to the traditional, open bay NICU. Time period 2 included infants admitted to the new private, single family room NICU. There was a 3 month period between Time period 1 and Time period 2 to ensure that there was no patient overlap. Stool samples and environmental samples were collected at 1 and 4 weeks after birth in both time periods. The objective of this study was to establish the gastrointestinal microbiome of infants born at less than 32 weeks gestation admitted to the exiting open bay NICU and compare it to the gastrointestinal microbiome of infants born at less than 32 weeks admitted to the new private, single family room NICU.

Official Title
-----------------
Impact of Transition to a New Single Patient Room NICU on Gastric Bacterial Colonization of Preterm Neonates Compared to a Traditional Open Bay NICU

Conditions
-----------------
Microbial Colonization, Preterm Birth

Intervention / Treatment
-----------------
* Other: Observational


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Less than 32 weeks gestation at birth Exclusion Criteria: Infants in Time period 2 that were admitted to the traditional, open bay NICU

Ages Eligible for Study
-----------------
Minimum Age: 1 Week
Maximum Age: 6 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Time period 1<br>Time period one included infants admitted to the current traditional, open bay NICU. | Other: Observational<br>* This was an observational study which involved collection of stool samples and environmental samples at 1 week and 4 weeks of life.<br>|
| Time period 2<br>Time period 2 included infants admitted to the private, single family room NICU. | Other: Observational<br>* This was an observational study which involved collection of stool samples and environmental samples at 1 week and 4 weeks of life.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Microorganisms identified in stool samples | Microorganisms identified in stool samples obtained at weeks 1 and 4 of life using the 16s rRNA sequencing based technique. | 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Microorganisms identified in environmental samples | Microorganisms identified in samples obtained from the counter, floor, and incubator top or inside wall at weeks 1 and 4 of life using the 16 s rRNA sequencing based technique. | 4 weeks |
¡Si, Yo Puedo Control Mi Diabetes!: A Diabetes Self-management Education Program for Hispanic/Latinos

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to evaluate the effectiveness of the íSi, Yo Puedo Controlar Mi Diabetes! (Yo Puedo) diabetes self-management education program.

Official Title
-----------------
¡Si, Yo Puedo Control Mi Diabetes!: A Diabetes Self-management Education Program for Hispanic/Latinos

Conditions
-----------------
Type 2 Diabetes, Hispanic/Latinos, Diabetes Self-management Education

Intervention / Treatment
-----------------
* Behavioral: diabetes self-management education


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Self-identification as Hispanic/Latino, over the age of 18 years of age, diagnosis of type 2 diabetes and willingness to participate in the diabetes self-management education class. Exclusion Criteria: non-diabetic persons, non English-speaking Hispanic/Latinos with type 2 diabetes -

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Parallel Assignment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: diabetes self-management education|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Non-Interventional, Multicenter Bicontact® E PMCF Study

Study Overview
=================
Brief Summary
-----------------
Prospective observational (non-interventional) cohort study, multi-centric in 5 study Centers in Japan to collect short term clinical and radiological results of the cementless Bicontact® E stem in a standard patient population used in routine clinical practice

Official Title
-----------------
Non-Interventional, Multicenter Bicontact® E PMCF Study

Conditions
-----------------
Degenerative Osteoarthritis, Rheumatoid Arthritis, Femoral Neck Fractures, Femoral Head Necrosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Indication for Bicontact E prosthesis THA Patients ≥ 18 years Patient not pregnant Written informed consent Exclusion Criteria: - Patients receiving a bipolar implantation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical Results | Hip Score of the Japanese Orthopaedic Association (JOA): three categories-movement, mental, and pain-each comprising 7 items, for a total of 21 items to be used as evaluation criteria for hip-joint function | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Thigh Pain | Pain as measured with the Visual Analog Scale (VAS): Visual analog scale [VAS] is a measure of pain intensity. It is a continuous scale comprised of a horizontal analog scale of 100 mm length. It is anchored by two verbal descriptors, one for each symptom extreme [no pain - worst imaginable pain]. | 1 year | 
| X-Ray evaluation | Radiological results (osteointegration, migration) | 1 year | 
| (Serious) Adverse Events | Complications: Adverse Events (AE) / Serious Adverse Events (SAE) | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Arthroplasty, Replacement, Hip
Genome-wide Association Study of Pituitary Tumors

Study Overview
=================
Brief Summary
-----------------
Pituitary adenomas is a very common disease, but the cause and genetics hasn't been identified. The investigators are going to use genome-wide association study to identify genes that may be related to pituitary adenomas.

Official Title
-----------------
Genome-wide Association Study of Pituitary Tumors

Conditions
-----------------
Pituitary Adenomas

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients diagnosed with pituitary adenomas Exclusion Criteria: patients with a family history of endocrine tumors
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
An Observational Study of Avastin (Bevacizumab) and Interferon Alpha 2a in Patients With Metastatic Renal Cell Cancer (VERA)

Study Overview
=================
Brief Summary
-----------------
This prospective observational study will evaluate the efficacy and safety of Avastin (bevacizumab) in combination with interferon alpha 2a in patients with previously untreated metastatic renal cell cancer. Data will be collected from each patient for up to 4 years.

Official Title
-----------------
An Open Label, Prospective, Observational, Local, Non-interventional Study of BeVacizumab (Avastin) and IntErpherone (IFN) Alpha 2a in Patients With Metastatic and Locally Advanced Renal Cell CAncer (VERA Study)

Conditions
-----------------
Renal Cell Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients, >/= 18 years of age Histologically confirmed metastatic renal cell cancer, clear cell type Eligible for treatment with Avastin and interferon alpha 2a according to local prescribing information Exclusion Criteria: Contraindications for Avastin or interferon alpha 2a treatment according to local Summary of Product Characteristics Known hypersensitivity to Avastin and/or interferon alpha 2a or any of its excipients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cohort<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression-free survival |  | approximately 4 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival |  | approximately 4 years | 
| Response rate |  | approximately 4 years | 
| Safety: Incidence of adverse events |  | approximately 4 years |
Assessment of the Anesthetic Effect on the Activity of Immune Cell in Patient With Colon Cancer

Study Overview
=================
Brief Summary
-----------------
Anesthetics agents has variety inflammation during the cancer surgery. This perioperative inflammation can influence to cancer metastasis or recurrence. The purpose of this study is to prove the variation of immune cell activity between preoperative and postoperative period.

Detailed Description
-----------------
The patients were allocated randomly to receive propofol or sevoflurane. Also, a total of 18ml of blood sample was obtained for total 3 times in consecutive order. immediate before anesthesia induction postoperative 1 hours postoperative 24 hours Serum in blood will be obtained and activity of helper T cell, natural killer cell and level of serum cytokine will be evaluated by flow cytometry or enzyme-linked immunosorbent assay

Official Title
-----------------
Assessment of the Anesthetic Effect on the Activity of Immune Cell in Patient With Colon Cancer

Conditions
-----------------
Colon Cancer

Intervention / Treatment
-----------------
* Drug: propofol group
* Drug: sevoflurane group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient who was planned to undergo colon cancer surgery. Exclusion Criteria: age < 20 years old history of hypersensitivity reaction in propofol or sevoflurane history of previous cancer patient with ongoing inflammation

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: propofol group<br>The patient who anesthetized by using propofol. | Drug: propofol group<br>* Patient will be anesthetized by using propofol infusion during operation<br>* Other names: propofol;|
| Other: sevoflurane group<br>The patient who anesthetized by using propofol. | Drug: sevoflurane group<br>* Patient will be anesthetized by using sevoflurane inhalation during operation<br>* Other names: sevoflurane;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| natural killer cell activity | change of percentage of natural killer cell (scores range from 0 to 100) | preoperative time. postoperative 1 hours and 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| helper T cell activity | change of percentage of helper T cell (scores range from 0 to 100) | preoperative time. postoperative 1 hours and 24 hours |
Association Between cd163 Gene Polymorphisms and Sepsis Among Chinese Han Population

Study Overview
=================
Brief Summary
-----------------
CD163 is a member of the scavenger receptor cysteine-rich family (SRCR) is exclusively expressed on cells of the monocyte lineage.CD163 acts to amplify inflammation and serves as a critical mediator of inflammatory response in the context of sepsis. This study was designed to investigate whether CD163 genomic variations were associated with the prognosis of sepsis. We sequenced 30 sepsis patients with CD163 gene of seventeen exons by PCR sequencing. When analyzing the results of sequencing, we found five gene polymorphisms located in exon-2,exon-5 and exon-11, respectively. Compare with the NCBI dbSNP and Hapmap database, one polymorphisms located in exon-2 is non-synonymous variation rs3210140, two polymorphisms located in exon-5 are synonymous variations rs4883264 and rs4883263, the last two located in exon-11 are synonymous variations rs61729512 and rs150018775 . Five common polymorphisms (rs2234237,rs2234246) within the CD163 gene were detected in 200 patients with severe sepsis and in 200 healthy control subjects. This study was explored that whether or not polymorphisms detected within the CD163 gene may play a major role in the predisposition to prognosis of sepsis in a Chinese Han cohort.

Official Title
-----------------
Association Between cd163 Gene Polymorphisms and Sepsis Among Chinese Han Population

Conditions
-----------------
Sepsis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Sepsis met the criteria recommended by 1991 ACCP/SCCM Joint Meeting and by the diagnostic criteria developed at the 2001 International Sepsis Definition Conference. Exclusion Criteria: (1) younger than 18 years of age; (2) acquired immunodeficiency syndrome; (3) reduced polymorphonuclear granulocyte counts (< 500 μL-1); (4) died within 24h after admission into the ICU, or refused to participate in the study, or declined treatment during the period of observation.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control<br>normal person under medical examination | |
| sepsis<br>SIRS plus inflammation | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CD163;, SNPs;, prognosis;, control（normal person）
Identification of Admission High Risk Elderly

Study Overview
=================
Brief Summary
-----------------
Objective: The study aim to establish high risk admission model and readmission model for elderly in Taiwan. Method: Investigators compare the clinical, epidemiological, and socioeconomic characteristics of admitted patients during 1 August,2011 to 31 July,2012. All patients will follow up to end of study to identify 14 days readmission and 30 days readmission to geriatic ward. Expected Outcomes: (1) To compare the prediction value of derivation cohort and validation cohort. (2) To identify high risk indicators of admission and readmission for elderly. (3) To determine the risk factors in admission elderly association with quality indicators.

Official Title
-----------------
Identification of Admission High Risk Elderly From Multiple Cohorts: a Pilot Study

Conditions
-----------------
Stroke, Pneumonia, Urinary Tract Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with age 65 year old above Patients admission to geriatric ward Exclusion Criteria: Patients with unstable vital sign Patients or dependants reject to sign inform consent.

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Admission High Risk<br>Admission High Risk | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determine percentages of high risk in elderly 14 days readmission to geriatric ward | Readmission in 14 days to geriatric ward is an important issue of elderly. | 1-year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Admission High Risk Elderly
Relation Between Bone Density and the Regulation of Mineral Metabolism in Renal Stone Formers

Study Overview
=================
Brief Summary
-----------------
Accumulating evidence indicated that renal calcium stone formers often exhibit a low bone density. Therefore we want to test the hypothesis, that the mineral (calcium) metabolism is differently regulated in calcium stone formers with low as opposed to high bone density.

Detailed Description
-----------------
There is epidemiological evidence associating renal calcium stones and decreased bone mineral density (BMD). The decreased BMD in calcium stone formers is linked to hypercalciuria and both subtypes, fasting as well as absorptive hypercalciuria are associated with a diminished BMD. Higher 1,25-vitamin D plasma concentrations and lower PTH levels are encountered under free-choice diet conditions in patients diagnosed with absorptive and fasting hypercalciuria when compared to normocalciuric stone formers. Reports studying the BMD of stone formers and its link with mineral metabolism variables and urinary calcium excretion under different calcium intakes are rare. We hypothesize now that PTH and 1,25-vitamin D change differently when calcium stone formers with high, intermediate and low BMD are challenged by a low calcium diet.

Official Title
-----------------
Relation Between Bone Mineral Density and the Regulation of Mineral Metabolism in Renal Stone Formers

Conditions
-----------------
Calcium Nephrolithiasis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: passage of at least one calcium containing kidney stone Exclusion Criteria: established cause of calcium stone formation (sarcoidosis, primary hyperparathyroidism etc.) creatinine clearance < 60 ml/min urinary tract infection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
calcium, calciuria, PTH, 1,25-vitamin D, Calcitriol, bone mineral density, osteodensitometry